Weekly Trademark Review April 26, 2016
This article was originally published in The Tan Sheet
OTC drug, personal care product and nutritional supplement trademark filings compiled by “The Tan Sheet” from Official Gazette of the U.S. Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps; and Class 5 – Pharmaceuticals.
You may also be interested in...
Beauty Market News: China Cosmetics Regulations Modernized, Florida Stops Local Oxybenzone Bans, More
L’Oreal acquires Thayers Natural Remedies; Unilever, L’Oreal remove ‘whitening,’ ‘fair’ from labels; China finalizes modernization of cosmetics regulations; and Florida governor signs law preventing local bans on oxybenzone.
The US Food and Drug Administration should require that outsourcing facilities collect bioavailability data for compounded bioidentical hormone replacement therapy products, while compounding pharmacies should be required to report adverse events to state pharmacy boards and the FDA. Such actions would help resolve some of the safety concerns for these products, says a 1 July report from the National Academy of Sciences, Engineering and Medicine.
Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.